Your session is about to expire
← Back to Search
Botulinum toxin type A for Parkinson's Disease
Study Summary
This trial is studying whether botulinum toxin type A can help relieve pain in the feet caused by dystonia in Parkinson's disease.
- Parkinson's Disease
- Dystonia
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 4 trial • 42 Patients • NCT02321436Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there comparable studies to this one that use Botulinum toxin type A?
"69 clinical trials involving Botulinum toxin type A are currently ongoing, with 23 in Phase 3. Most of these trials are based in Farmington Hills, Michigan, but there are 787 locations running these trials in total."
What medical conditions are most often treated with Botulinum toxin type A?
"Botulinum toxin type A is most commonly used to treat urinary incontinence. It can also be prescribed to treat other conditions such as spinal cord, botox, overactive bladder syndrome (OABs)."
Does this research allow for patients who are elderly to participate?
"The current study is looking for individuals that are over 30 and younger than 100."
How can I sign up to participate in this clinical trial?
"40 individuals with a diagnosis of parkinson disease, aged between 30 and 100 years old, who have not received botulinum toxin type A (BTXA) treatment in the last 6 months are needed for this study. Applicants must also be stable on their PD and pain medications for at least 30 days and have unresponsive foot dystonia that is not helped by changes to their antiparkinsonian medication schedule. Subjects with bilateral foot dystonia will be injected in the side where the symptoms are more severe."
Is this experiment recruiting new participants at this time?
"Yes, the most recent information on clinicaltrials.gov suggests that this study is still recruiting patients. The listing was first posted on January 12th, 2021 and was updated on May 16th, 2022."
How many people are part of this research project?
"That is correct. Currently, the clinical trial is recruiting patients. It was originally posted on 2021-01-12, and the most recent update was on 2022-05-16. The trial is seeking 40 patients from 1 site."
What are we hoping to learn from this clinical trial?
"The goal of this trial is to Change in Likert Visual Analogue Scale, which will be evaluated over a 6 and 12 weeks during the parallel group phase and at 24 weeks during the open-label phase. Secondary outcomes include Change in Parkinson's disease 39 item Quality of life questionnaire and Change in Movement Disorder Society Unified Parkinson disease Rating Scale Parts 1-4 (MDS-UPDRS) ON medication. The study also aims to measure Change in Clinical Global Impression Scale."
Share this study with friends
Copy Link
Messenger